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Impact of HIV and Type 2 diabetes 
on Gut Microbiota Diversity, 
Tryptophan Catabolism and 
Endothelial Dysfunction
Hedda Hoel1,2,3,4,5, Malene Hove-Skovsgaard6,7, Johannes R. Hov  1,2,3,8,9, Julie Christine 
Gaardbo6,7, Kristian Holm1,3,8, Martin Kummen1,2,3,8, Knut Rudi10, Felix Nwosu10,  
Jørgen Valeur11, Marco Gelpi6,7, Ingebjørg Seljeflot3,12,13, Per Magne Ueland14, Jan Gerstoft6, 
Henrik Ullum15, Pål Aukrust1,2,3,5, Susanne Dam Nielsen6,7 & Marius Trøseid1,2,3,5
HIV infection and type 2 diabetes are associated with altered gut microbiota, chronic inflammation, 
and increased cardiovascular risk. We aimed to investigate the combined effect of these diseases 
on gut microbiota composition and related metabolites, and a potential relation to endothelial 
dysfunction in individuals with HIV-infection only (n = 23), diabetes only (n = 16) or both conditions 
(n = 21), as well as controls (n = 24). Fecal microbiota was analyzed by Illumina sequencing of the 16 S 
rRNA gene. Markers of endothelial dysfunction (asymmetric dimethylarginine [ADMA]), tryptophan 
catabolism (kynurenine/tryptophan [KT]-ratio), and inflammation (neopterin) were measured by 
liquid chromatography-tandem mass spectrometry. The combination of HIV and type 2 diabetes was 
associated with reduced gut microbiota diversity, increased plasma KT-ratio and neopterin. Microbial 
genes related to tryptophan metabolism correlated with KT-ratio and low alpha diversity, in particular 
in HIV-infected with T2D. In multivariate analyses, KT-ratio associated with ADMA (β = 4.58 [95% CI 
2.53–6.63], p < 0.001), whereas microbiota composition per se was not associated with endothelial 
dysfunction. Our results indicate that tryptophan catabolism may be related to endothelial dysfunction, 
with a potentially detrimental interaction between HIV and diabetes. The potential contribution of 
gut microbiota and the impact for cardiovascular risk should be further explored in prospective studies 
powered for clinical end points.
HIV affects more than 35 million people worldwide, and with increasing use of antiretroviral treatment (ART) life 
expectancy has increased substantially1. In an ageing HIV-infected population, the relative burden of non-AIDS 
comorbidities such as cardiovascular and related metabolic disorders is increasing2. In addition to traditional risk 
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factors such as hyperlipidemia and smoking, chronic inflammation may contribute to increased risk and progres-
sion of cardiovascular and metabolic comorbidities3.
Type 2 diabetes (T2D) is one of the most common chronic diseases worldwide, and like HIV characterized by 
chronic inflammation, atherosclerosis and increased cardiovascular risk4. Although it is debated if the risk of T2D 
is higher in HIV-infected patients than in the general population5,6, an ageing HIV-infected population in combi-
nation with a worldwide emerging diabetes epidemic is rapidly becoming a clinical challenge requiring increased 
attention and knowledge about the potential interacting effect of these two chronic diseases.
Endothelial dysfunction occurs in early stages of the atherosclerotic process and is also an early feature of 
T2D4. Asymmetric dimethylarginine (ADMA) is a well-established biomarker for nitric oxide (NO)-dependent 
endothelial dysfunction in both HIV and T2D7–9. We have recently shown an additive effect of HIV and T2D on 
endothelial dysfunction as measured by ADMA10. Previous works have suggested a potential role of inflammation 
in this patient group, with low levels of IL-10 production in HIV-infected with diabetes11, and soluble TNFR1 
predicting incident diabetes in HIV-infected on ART12, but the potential triggers remain unknown.
A healthy gut microbiota contains a highly diverse population of bacteria which is involved in the regulation 
of numerous metabolic and inflammatory pathways. The gut microbiota exerts its functions not only in the gut, 
but also systemically, and is altered in metabolic and cardiovascular diseases such as obesity, T2D and atheroscle-
rosis13–15. During the last years, an altered gut microbiome has also been well documented in HIV infection. Of 
note, the gut microbiota changes observed in several HIV-infected cohorts16–19 partly overlap with those found in 
patients with obesity and T2D, with reduced biodiversity and lower relative abundance of commensal microbes, 
including butyrate-producing bacteria13,15,20. There is, however, a great variability in the findings, partly due to 
variations in sampling and sequencing methods as well as ethnicity, diet, age, geography, ART and modes of 
transmission, including sexual practice16–19,21–26. Whereas reduced alpha diversity is found in several cohorts of 
untreated HIV infection, and partly relates to low CD4 count, studies have been conflicting regarding alpha diver-
sity in ART-treated cohorts18,21,23,26. Hence, a specific HIV-associated dysbiosis remains to be defined.
A particular finding reported in HIV-infected cohorts is that microbiota alterations have been associ-
ated with tryptophan catabolism and systemic inflammation19,26. Tryptophan is an essential amino acid, and is 
mainly catabolized through the kynurenine pathway to metabolites collectively called kynurenines. The first and 
rate-limiting step in the kynurenine pathway is the oxidative cleavage of the indole ring of tryptophan to form 
N-formyl-kynurenine, which is spontaneously decomposed to kynurenine. This step is catalysed by indolamine 
2,3-dioxygenase-1 (IDO-1), which is induced by interferon (IFN)-γ19. Altered tryptophan metabolism has been 
linked to immune activation and increased mortality in HIV-infected individuals27,28, and has been associated with 
increased cardiovascular mortality in the general population29,30. Recently, tryptophan catabolism through the 
kynurenine pathway was even shown to be predictive of incident T2D in individuals with coronary artery disease31.
Disturbed gut microbiota composition, IFN-γ-induced tryptophan catabolism and endothelial dysfunction 
could therefore represent pathogenic pathways potentially interacting in HIV infection and T2D. We set out to 
investigate this hypothesis in a cohort of individuals with HIV-infection only, T2D only or both condition, as well 
as controls.
Research Design and Methods
Study design and participants. The total study cohort consisted of 100 participants in a cross-sectional 
study10. Gut microbiota samples were available from 84 participants who were included in the present study: 21 
HIV-infected individuals with T2D (HIV+T2D), 23 HIV-infected without T2D (HIV only), 16 individuals with 
T2D without HIV (T2D only) and 24 individuals without HIV and T2D (denoted controls). Study participants 
were included from Departments of Infectious Diseases, University Hospital of Copenhagen, Rigshospitalet and 
Hvidovre Hospital, from Department of Endocrinology, and Center of Inflammation and Metabolism, University 
Hospital of Copenhagen, Rigshospitalet. Exclusion criteria were immunosuppressive treatment, acute infections, 
malignancy, and pregnancy.
All HIV-infected individuals were on stable ART for at least 11 months, with the exception of five patients who 
participated in a switch study from abacavir/lamivudine to emtricitabine/tenofovir disoproxil fumarate. Time on 
ART did not differ significantly between the HIV only group and the HIV+ T2D group. With the exception of 
three episodes with blips (<200 copies/mL), all individuals remained virally suppressed (i.e., <40 copies/mL) dur-
ing time on ART. All persons with T2D were treated with diet and/or oral anti-diabetics and/or insulin, and had a 
normal fasting glucose (<6.1 mmol/L) and HbA1c <6.2% (44 mmol/mol). The proportion of individuals receiv-
ing oral anti-diabetics and insulin did not differ significantly between the T2D only group and the HIV +T2D 
group (Table 1).
Apparently healthy controls, based on medical history and clinical examination, were recruited among hos-
pital staff. The study was performed in accordance with the declaration of Helsinki, approved by the local ethical 
committee (H-4-2012-076 CIM VEK) and the Danish Data Protection Agency, and written informed consent was 
obtained from all subjects.
Biochemistry and blood sampling. Fasting blood samples were collected, and glucose, HbA1c, lipid 
parameters, CD4 T cell count and HIV RNA were measured as routine analyses. To assess endothelial dysfunc-
tion, L-arginine and ADMA were measured in snap-frozen EDTA-plasma by high performance liquid chro-
matography (HPLC) and precolumn derivatization with o-phthaldialdehyde (Sigma Chemicals Co, St.Louis, 
MO, USA) as described10. Inter- and intra-assay CV’s were <5%. Plasma levels of neopterin, kynurenine and 
tryptophan were analyzed at BEVITAL (www.bevital.no) by liquid chromatography–tandem mass spectrometry 
(LC-MS/MS) as previously described32. Kynurenine/tryptophan (KT)-ratio was used as a measure of IDO-1 acti-
vation19, and plasma levels of neopterin as a measure of IFN-γ activity33–36.
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DNA extraction from stool samples and 16 s rRNA sequencing of gut microbiota. Two stool 
samples without preservatives were collected from each participant, shipped by mail to Rigshospitalet and stored 
at −80 °C until further use. The samples were processed and DNA was extracted as previously described18. 
Extracted DNA was PCR amplified targeting the 16 S rRNA gene using universal primers (for all prokaryotic 
organisms) flanking V3-V4 region of 16 S gene modified with addition of TruSeq Illumina adapters. PCR ampli-
fication consisted of 30 cycles of 95 °C for 30 seconds, 50 °C for 30 seconds, 75 °C for 45 seconds and followed by a 
final elongation at 72 °C for 7 minutes. Each PCR-amplicon was quantified using Quant-iTTM PicoGreen® dsDNA 
kit (Life Technologies, USA), then normalized and pooled in equal concentrations. The pooled amplicons were 
purified with E.N.Z.A. Cycle Pure Kit (Omega Bio-Tek, Norcross, Georgia, USA) and eluted in 0.1 mM Tris buffer 
(pH 8.5). After E.N.Z.A. kit purification, there was a final DNA quantification of the amplicon pool. Sequencing 
was performed on the Illumina MiSeq platform using the 250 base pair, paired end protocol (Illumina, San Diego, 
California, USA) at Norwegian Sequencing Centre (Oslo, Norway).
Fecal calprotectin. Fecal samples were extracted by using Calex Cap Device (Bühlmann Laboratories AG, 
Schönenbuch, Switzerland), and calprotectin concentrations were analyzed in the extracts by using an 
enzyme-linked immunoassay test (Bühlmann fCAL ELISA, Bühlmann Laboratories AG, Schönenbuch, 
Switzerland), according to the manufacturer’s instructions. All extracts were analyzed in duplicates and fecal 
calprotectin levels were reported as mean values of the duplicates (mg/kg). As a large proportion of samples were 
below the lower limit of detection (40 mg/kg), the values were categorized as non-detectable, normal or elevated 
(>100 mg/kg).
Sequence analysis and bioinformatics. Paired-end reads were merged with FLASH (Fast length adjust-
ment of short reads to improve genome assemblies) version 1.2.1137. The merged reads were de-multiplexed, 
pre-processed and subsequently analyzed with QIIME (Quantitative Insights Into Microbial Ecology) version 
1.8.0 software package38. Taxonomy classification was performed using “closed-reference OTU picking” against 
the Greengenes version 13.8 OTU database with 97% cluster identity. For each individual, we used the sample 
with the highest read count after pre-processing. Alpha diversity was calculated using number of observed bacte-
rial species and Shannon diversity index as previously described18. To assess the functional characteristics of gut 
microbiota alterations, we performed a PICRUSt (Phylogenetic Investigation of Communities by Reconstruction 
of Unobserved States) analysis39, normalized to 5,337 reads per sample.
Controls (n = 24)
Type 2 diabetes 
(n = 16) HIV (n = 23)
HIV + type 2 
diabetes (n = 21) P
Age (years) 57 (54–60) 57 (54–60) 54 (51–58) 57 (54–60) 0.512
Gender (% male) 92 69 96 90 0.061
Smokers (%) 79 88 78 57 0.154
Use of medication (%)
   PI — — 65d 33 0.035
   NNRTI — — 35d 71 0.015
   Statins 12b,d 69 4b,d 71  < 0.001
   Betablockers 0d 6d 5d 29 0.006
   ACE inhibitor/ATII antagonist 21d 40 9b,d 62 0.007
   Oral antidiabetics — 75 — 81 0.663
   Insulin — 13 — 24 0.384
Hypertension (%) 29d 48d 13b,d 81 <0.001
HIV transmission (MSM, heterosexual, IDU) (%) — — 87/3/0 62/15/23 0.131
Time on stable ART (months) — — 22.5 (12.4–32.6) 25.4 (13.2–37.7) 0.693
Physical activity ( < 1/1–2/ ≥ 3 times/week) 17/38/45d 31/31/38 41/27/32 45/35/20 0.023
CD4 count (cells/μL) 861 (721–1000)c,d 1131 (921–1342)c,d 612 (490–734) 646 (511–780) <0.001
LDL cholesterol (mmol/L) 3.5 (3.2–3.8)b,d 2.3 (1.8–2.8) 3.4 (3.0–3.7)b,d 2.4 (2.0–2.8) <0.001
HbA1c (mmol/mol) 37 (36–38)b,d 57 (51–62) 35 (34–37)b,d 48 (44–52) <0.001
HbA1c (%) 5.5 (5.4–5.6) 7.4 (6.8–7.8) 5.4 (5.3–5.5) 6.5 (6.2–6.9)
BMI (kg/m2) 25 (24–26) 28(26–30) 25 (23–27) 26 (23–28) 0.064
Triglycerides (mmol/L) 1.4 (1.0–1.9)d 2.1 (1.5–2.8) 1.9 (1.3–2.4) 2.7 (1.9–3.5) 0.026
HDL cholesterol (mmol/L) 1.6 (1.4–1.8)b,d 1.3 (1.1–1.5) 1.4 (1.2–1.5) 1.2 (1.0–1.4) 0.010
Systolic BP (mmHg) 135 (129–141) 136 (130–142) 128 (122–134) 132 (123–140) 0.322
ADMA (µmol/L) 0.55 (0.52–0.58)c,d 0.60 (0.54–0.65) 0.60 (0.56–0.63)d 0.67 (0.62–0.72) 0.001
Table 1. Demographic and biochemical characteristics of the study population. P-value refers to one-way 
ANOVA for continuous data and Chi-Square or Fisher’s exact test for categorical data. Results are given as % 
or mean and 95% CI. b,c,d Refers to t-test; bp < 0.05 vs. T2D, cp < 0.05 vs. HIV, dp < 0.05 vs. HIV + T2D. LDL: 
low density lipoprotein, HDL: high density lipoprotein, BMI: body mass index, BP: blood pressure, ADMA: 
Asymmetric dimethylarginine, MSM: men who have sex with men, IDU: intravenous drug use.
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Statistics. Continuous data were analyzed using one-way ANOVA for comparison of multiple groups, fol-
lowed by t test for between group comparisons, with the exception of relative abundance of bacterial species that 
were not normally distributed. Hence, relative abundance of bacterial species was compared with Kruskal-Wallis 
test for comparison of multiple groups, followed by Mann Whitney U test for between group comparisons. 
Categorical data were compared with Chi squared test. Correlations were performed with Pearson correlation, 
and only statistically significant correlations (p < 0.05) are reported. False-discovery rate (FDR) was calculated 
according to Benjamini-Hochberg, and denoted QFDR. Potential predictors of endothelial dysfunction were fur-
ther investigated in a stepwise linear regression analysis. Skewed data were log-transformed before Pearson cor-
relations and linear regression analyses. The statistical analyses were performed with SPSS software, version 21.0 
(IBM SPSS Statistics), and FDR-values were calculated in R (v3.4).
Data availability. The datasets generated during and/or analyzed during the current study are not publicly 
available due to Norwegian legislation about general data protection regulation, but are available from the corre-
sponding author on reasonable request.
Results
Baseline characteristics. Baseline characteristics are given in Table 1. There was more use of ACE-
inhibitors, angiotensin 2 blockers and statins in patients with T2D irrespective of HIV-status, whereas use of 
beta-blockers was more prevalent in HIV-infected patients with T2D. HIV-infected patients with T2D were more 
often treated with non-nucleoside reverse transcriptase inhibitors (NNRTIs) and less often with protease inhibi-
tors (PIs) compared to HIV-infected patients without T2D. Those with combined T2D and HIV infection had the 
highest levels of triglycerides and the lowest levels of high-density lipoprotein (HDL) cholesterol, but there was no 
difference in HbA1c in patients with T2D according to HIV status. Furthermore, low-density lipoprotein (LDL) 
cholesterol was lower in patients with T2D irrespective of HIV status, probably reflecting higher use of statins. 
Finally, there was a higher proportion of sedentary individuals (exercising <once/week) in the HIV+T2D group 
compared to controls.
Impact of HIV, T2D and both on endothelial dysfunction, tryptophan metabolism, and inflamma-
tion. As previously described, HIV-infected patients with T2D had higher concentration of ADMA as a marker 
of endothelial dysfunction compared with controls and HIV-infected patients without T2D10 (Table 1). In addition, 
HIV-infected patients had higher plasma KT-ratio as a marker of increased IDO-1 induced tryptophan metabolism 
and higher levels of the pro-inflammatory marker neopterin, with the highest levels in those with accompanying 
T2D (Fig. 1A,B). In contrast, T2D alone was not associated with increased KT-ratio or neopterin levels.
HIV-infected patients with T2D have an altered gut microbiota with reduced alpha diver-
sity. As depicted in Fig. 1C and D, the lowest alpha diversity (number of observed bacterial species) was found 
in HIV-infected patients with T2D, followed by T2D alone, HIV alone, and healthy controls. Of note, there was 
no significant difference between HIV alone and healthy controls whereas HIV + T2D had a significantly lower 
number of observed bacterial species compared to both HIV alone and controls. The same pattern was seen when 
applying the Shannon diversity index, with the lowest alpha diversity in HIV + T2D, significantly lower than HIV 
alone and controls (p for trend = 0.003).
Diabetes treatment, Framingham score and mode of HIV transmission are associated with 
alpha diversity. Factors associated with alpha diversity measures are given in Table 2, including physical 
activity and HDL cholesterol which were associated with higher alpha diversity measures, and smoking and 
Framingham risk score being associated with lower alpha diversity. With respect to diabetes treatment, met-
formin was associated with higher alpha diversity, as previously reported13. Concerning HIV transmission, there 
was a higher alpha diversity in men who have sex with men (MSM), also in line with a recent report23. In contrast, 
BMI, time on ART, CD4+ T cell count, type of ART (PI/NNRTI) or use of statins were not associated with alpha 
diversity measures (data not shown).
HIV-infected patients with T2D have altered gut microbiota composition and increased fecal 
calprotectin levels. Looking at microbiota composition in more detail, no significant differences were 
observed between the groups among the major bacterial phyla. Significantly different taxa on order and genus 
level are summarized in Supplementary Table S1 showing differences in HIV + T2D as compared with the other 
groups. On order level, there was an expansion of Enterobacteriales and Lactobacillales in the HIV + T2D group, 
the latter being driven by an increase in Streptococcus on genus levels. Among the more abundant taxa on the 
genus level, microbes from the family of Lachnospiracea (Lachnospira, Lachnobacterium, Anaerostipes) were 
depleted in the HIV + T2D group. Although the Lachnospiracea family is known for its capacity to produce 
butyrate, the overall capacity for butyrate metabolism as predicted by a PICRUSt analysis, did not differ between 
the groups (p = 0.70).
Of note, none of the bacterial taxa were significantly different between the groups after FDR adjustment, and 
differences in individual bacterial taxa should therefore be interpreted with caution. In order to capture the over-
all local inflammation in the gut, we measured fecal calprotectin levels, finding a higher fraction of individuals 
with elevated calprotectin levels (>100 mg/kg feces) in HIV + T2D (43%) compared to the other groups (HIV 
only 22%, T2D 13%, controls 17%, p for trend = 0.048). However, log-transformed fecal calprotectin levels did 
not correlate with soluble markers, including ADMA (r = 0.11, p = 0.308), L-arginin/ADMA ratio (r = −0.09, 
p = 0.439), KT-ratio (r = 0.12, p = 0.281), neopterin (r = 0.11, p = 0.307) or log-transformed C-reactive protein 
(CRP) levels (r = 0.09, p = 0.440).
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Tryptophan catabolizing bacteria are associated with KT-ratio and plasma neopterin but not 
with endothelial dysfunction. We next examined the potential impact of tryptophan metabolizing 
microbes in the gut microbiota by performing a PICRUSt analysis. Bacterial taxa contributing to tryptophan 
metabolism belonged mainly to the phylum Proteobacteria, including Burkholderia, Pseudomonas, and Bacillus, 
as previously reported19 (Supplementary Table S2). Bacterial genes related to tryptophan metabolism correlated 
with KT-ratio and neopterin in the total population (r = 0.33, p = 0.002 and r = 0.38, p < 0.001) and particularly 
in HIV-infected patients with T2D (r = 0.52, p = 0.015 and r = 0.57, p = 0.007). Furthermore, tryptophan metab-
olizing microbes correlated negatively with gut microbiota diversity and again, these correlations were stronger 
in HIV-infected with T2D (Table 3).
Figure 1. The impact of HIV, T2D and both (HIV + T2D) on (A) tryptophan catabolism (KT-ratio), (B) 
inflammation (neopterin), (C and D) gut microbiota diversity (number of observed bacterial species and 
Shannon diversity index). Controls (red), HIV only (blue), T2D only (green) and HIV-infected with T2D 
(orange). *p < 0.05 vs. controls, #p < 0.05 vs. T2D only, †p < 0.05 vs. HIV only.
Observed bacterial species p QFDR Shannon diversity Index p QFDR
MSM (yes/no) 363(339–386) 321 (290–351) 0.030 0.054 6.06 (5.85–6.27) 5.56 (5.21–6.90) 0.015 0.038
Physical active (< 1/1–2/week) 355 (332–378) 332 (309–356) 0.151 0.164 5.91 (5.69–6.14) 5.63 (5.36–5.89) 0.038 0.057
Insulin (yes/no) 256 (204–308) 355 (343–367) <0.001 <0.001 4.69 (4.21–5.18) 5.94 (5.83–6.05) <0.001 <0.001
Metformin (yes/no) 336 (313–359) 296 (255–339) 0.066 0.099 5.75 (5.55–6.00) 5.21 (4.80–5.64) 0.017 0.051
Betablocker (yes/no) 300 (240–359) 351 (339–364) 0.017 0.038 5.51 (4.94–6.09) 5.87 (5.74–6.01) 0.110 0.110
Statin (yes/no) 332 (309–355) 355 (339–370) 0.094 0.121 5.69 (5.45–5.92) 5.92 (5.76–6.08) 0.089 0.110
Smoking (yes/no) 317 (288–346) 356 (343–370) 0.007 0.021 5.58 (5.27–5.89) 5.92 (5.78–6.02) 0.023 0.052
HDL cholesterol r = 0.20 0.066 0.099 r = 0.24 0.030 0.054
Framingham 10 year CVD risk r = −0.49 <0.001 <0.001 r = −0.42 <0.001 <0.001
Table 2. Association between covariates and gut microbiota diversity. Covariates with p < 0.10 are given. 
Data as mean (95% CI). Smoking and HDL cholesterol are part of the Framingham 10 year CVD risk, and 
were not entered as separate covariates in the multivariate linear regression model. MSM: men who have sex 
with men. MSM status was only available in HIV infected individuals. MSM status “no” refers to heterosexual 
transmission, IDU and unknown transmission.
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Among the factors potentially confounding alpha diversity (as shown in Table 2), MSM status was associated 
with lower predicted abundance of tryptophan metabolizing microbes (median 4609 [IQR 897] vs. 5473 [IQR 
499], p = 0.002). Of note, these factors, including MSM status, were not associated with KT-ratio. Tryptophan 
metabolizing microbes, although being correlated with KT-ratio and neopterin, did not correlate with endothe-
lial dysfunction (Table 3). CRP levels correlated inversely with alpha diversity measures but not with markers of 
endothelial dysfunction (Table 3).
Increased tryptophan catabolism is associated with endothelial dysfunction in multivariate 
analyses. As shown in Table 3, KT-ratio and neopterin were positively correlated with ADMA and negatively 
correlated with L-arginine/ADMA-ratio, suggesting an association between systemic inflammation, altered tryp-
tophan metabolisms and endothelial dysfunction. Notably, these correlations were stronger in HIV-infected with 
T2D (Table 3).
To further investigate potential predictors of endothelial dysfunction, we performed a stepwise multivariate 
linear regression analysis with ADMA as dependent variable, and KT-ratio, group, traditional cardiovascular 
risk factors, gut microbiota diversity and factors affecting the gut microbiota (Table 2) as covariates. KT-ratio, 
log-transformed CRP, group, observed bacterial species, physical activity, diabetes treatment (insulin, oral), mode 
of HIV transmission (MSM, others), and Framingham 10 year CVD score were included in the multivariate 
model. Neopterin was excluded from the model due to the close correlation with KT-ratio (r = 0.78, p < 0.001). 
KT-ratio was associated with ADMA in multivariate analyses (Fig. 2). Hence, higher KT-ratio was associated with 
higher ADMA reflecting increased endothelial dysfunction (β = 4.58 [95% CI 2.53–6.63], p < 0.001) also after 
adjusting for confounders.
Discussion
The main findings in the present study can be summarized as follows: i) The combination of HIV and T2D 
was associated with lower gut microbiota diversity, increased tryptophan catabolism, and higher levels of the 
pro-inflammatory marker neopterin, ii) gut microbiota diversity was negatively associated with smoking and 
Framingham score, and positively associated with metformin treatment, physical activity and mode of HIV trans-
mission (MSM), iii) microbes encoding genes related to tryptophan metabolism were associated with KT-ratio 
and neopterin but not with endothelial dysfunction, whereas iv) tryptophan catabolism as measured by KT-ratio 
was associated with markers of endothelial dysfunction in multivariate analyses.
Our findings suggest that the combination of HIV and T2D have detrimental effects on systemic inflammation 
and tryptophan catabolism, which potentially may promote endothelial dysfunction. Progressive HIV-infection 
is characterized by chronic inflammation and IDO-1 activation, and increased KT-ratio has been associated 
with non-AIDS defining morbidity in HIV-infected US subjects on suppressive ART40. Interestingly, a study 
showed that greater decline in KT-ratio after 6 months of ART predicted a lower carotid intima media thickness 
in Ugandan individuals receiving ART41. The present study is, however, to the best of our knowledge, the first to 
link tryptophan catabolism to markers of endothelial dysfunction, and notably, these associations were particu-
larly strong in subjects with both HIV infection and T2D.
Approximately 95% of dietary tryptophan is catabolized to kynurenine, which has immunosuppressive prop-
erties, partly by inhibiting T-cell proliferation and depleting Th17 cells, which in turn disfavours the mucosal 
barrier, thereby promoting low grade endotoxemia and T cell activation42. Activated T cells produce IFN-γ, which 
in turn activates tryptophan catabolism through upregulation of IDO-1, neopterin is almost exclusively released 
from IFN-γ activated monocytes/macrophages33, and plasma neopterin levels are associated with progressive 
HIV infection34–36.
Whereas plasma kynurenines and IFN-γ mediated immune activation have been associated with increased 
cardiovascular mortality in the general population29,30, and the metabolites of the kynurenine pathway may act as 
biomarkers for atherosclerotic disease, the mechanistic impact of activation of these pathways is not completely 
Variable
Gut microbiota diversity Endothelial dysfunction
Observed species Shannon Index L-Arginine/ADMA ADMA
Total population
HIV + type 2 
diabetes Total population
HIV + type 2 
diabetes Total population
HIV + type 2 
diabetes
Total 
population
HIV + type 
2 diabetes
Bacterial 
tryptophan 
metabolism
r = −0.29, p = 0.007 r = −0.54, p = 0.012 r = −0.47, p < 0.001 r = −0.73, p < 0.001 r = −0.03, p = 0.824 r = −0.40, p = 0.083 r = 0.12,p = 0.267
r = 0.29,
p = 0.222
KT-ratio r = −0.25, p = 0.024 r = −0.28, p = 0.216 r = −0.22, p = 0.012 r = −0.25, p = 0.824 r = −0.24, p = 0.029 r = −0.60, p = 0.006 r = 0.45,p < 0.001
r = 0.56,
p = 0.010
Neopterin r = −0.29, p = 0.008 r = −0.40, p = 0.074 r = −0.25, p = 0.020 r = −0.31, p = 0.173 r = −0.27, p = 0.014 r = −0.40, p = 0.079 r = 0.43,p < 0.001
r = 0.47,
p = 0.037
CRP r = −0.30, p = 0.009 r = −0.32, p = 0.166 r = −0.29, p = 0.014 r = −0.35, p = 0.135 r = −0.21, p = 0.075 r = −0.20, p = 0.409 r = 0.15,p = 0.209
r = 0.30,
p = 0.209
Table 3. Correlations between alpha diversity measures, endothelial dysfunction and bacterial genes related to 
tryptophan metabolism, KT-ratio and inflammation in the total study population (n = 84) and the HIV-infected 
individuals with type 2 diabetes (n = 21). Data as Pearson correlations. Pearson correlations > 0.5 in bold. 
ADMA: Asymmetric dimethylarginine, CRP: C-reactive protein, KT: Kynurenin/Tryptophan. CRP-levels were 
log-transformed before correlation analyses.
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understood. Thus, whereas downstream metabolites of kynurenine seem to accelerate endothelial apoptosis and 
dysfunction in vivo43, and IDO-1 activation appears to promote atherosclerosis in mice through reduced IL-10 
expression44, Zhang et al. identified atheroprotective effects of 3-HAA, a downstream tryptophan metabolite45. 
Also, systemic IDO-1 inhibition by 1-methyl-tryptophan resulted in increased atherosclerosis in mice46, implying 
that upregulation of IDO-1 may play a protective role against atherosclerosis. Nonetheless, our results suggest 
that IFN-γ activity and tryptophan catabolism may be closely linked to endothelial dysfunction, in particular in 
HIV-infected with T2D. Moreover, a recently published study showed that kynurenic acid-to-tryptophan ratio was 
associated with progression of carotid artery atherosclerosis in well-treated HIV patients47. However, if these asso-
ciations represent harmful or counteracting beneficial effects of these metabolites will need to be further clarified.
HIV-associated alterations of the gut microbiota have been associated with systemic inflammation and tryp-
tophan catabolism19,26. Our results confirm these findings, and even suggest that the association between tryp-
tophan metabolising microbes and KT-ratio may be stronger in HIV-infected patients with T2D. Of note, the 
abundance of tryptophan metabolizing microbes was lower in MSM, which to our knowledge is a novel obser-
vation. Given the large diversity of the present study population with respect to mode of HIV transmission, 
comorbidities and medication, it is not possible to predict the potential contribution from the gut microbiota on 
tryptophan catabolism measured by KT-ratio. Nevertheless, KT-ratio was not affected by MSM-status or other 
potential confounders of gut microbiota composition.
In the present study, we found the largest gut microbiota alterations with low alpha diversity in HIV-infected 
patients with T2D, but several factors beyond the disease states could have influenced our findings. First, studies 
have been conflicting regarding alpha diversity in HIV-infected on ART, with some but not all studies reporting 
reduced diversity18,21,23, and in the present study, we found a reduced diversity only in HIV-infected with T2D. 
Second, recent studies have implicated MSM status as a potential confounder, being associated with higher, not 
lower alpha diversity23,48, in line with higher diversity among MSM in the present study. Third, metformin treat-
ment was associated with higher diversity in line with a recent publication suggesting that the microbiota medi-
ates some of the therapeutic effects of metformin through short-chain fatty acid production13. Finally, physical 
activity was associated with higher diversity and smoking with a lower diversity of the gut microbiota, in line with 
previous studies reporting higher bacterial diversity in individuals with cardiorespiratory fitness49 and increasing 
diversity after smoking cessation50. Hence, all of the above mentioned factors are potential confounders of the gut 
microbiota composition, which make direct comparison between the groups difficult.
However, the association of gut microbiota composition and KT ratio and neopterin in HIV-infected with 
T2D may represent a link between altered gut microbiota and activation of systemic inflammatory pathways. This 
could include the promotion of endothelial dysfunction as suggested by the independent association between KT 
ratio and ADMA, and this hypothesis should be further investigated in properly designed studies that also include 
longitudinal follow-up.
The main limitations of the present study include the cross-sectional design and a study cohort with several 
comorbidities and treatment modalities, which precludes any conclusions on causality. In particular, the lack of 
MSM status in the control group consisting of hospital staff, and the lack of nutritional data are major limitations, 
and comparison between groups should be interpreted with caution. Moreover, the number of individuals in 
each group was relatively low. Furthermore, the use of PICRUSt instead of full metagenomic shotgun sequencing 
represents a limitation for the assessment of functional aspects of the gut microbiota. The strengths of this explor-
atory study include the use of well-established protocols for gut microbiota sequencing and metabolomics, and 
the comparison of groups with HIV infection only, T2D only and both conditions.
Figure 2. Association (Pearson correlation) between tryptophan catabolism (KT-ratio) and endothelial 
dysfunction assessed by ADMA in the total study population; controls (red), HIV only (blue), T2D only (green) 
and HIV-infected with T2D (orange).
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In conclusion, our results may relate systemic inflammation and tryptophan catabolism to endothelial dys-
function, with a potentially detrimental interaction between HIV and T2D. The potential contribution of the gut 
microbiota and the impact for increased cardiovascular risk should be further explored in prospective studies 
powered for clinical end points and stratified for diabetes and MSM status.
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